Michael C Wadman1, Shelly S Schwedhelm2, Suzanne Watson3, John Swanhorst4, Shawn G Gibbs5, John J Lowe5, Peter C Iwen6, A Kim Hayes7, Susie Needham3, Daniel W Johnson8, Daniel J Kalin9, Wesley G Zeger10, Robert L Muelleman9. 1. Department of Emergency Medicine, University of Nebraska Medical Center, Omaha, NE. Electronic address: mwadman@unmc.edu. 2. Emergency Department, Trauma, Emergency Preparedness Services, Nebraska Medicine, Omaha, NE; Nebraska Biocontainment Unit, Nebraska Medicine, Omaha, NE. 3. Emergency Services, Nebraska Medicine, Omaha, NE. 4. Nebraska Biocontainment Unit, Nebraska Medicine, Omaha, NE; Emergency Services, Nebraska Medicine, Omaha, NE. 5. Department of Environmental, Agricultural, and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, NE; Nebraska Biocontainment Unit, Nebraska Medicine, Omaha, NE. 6. Department of Pathology and Microbiology, Nebraska Public Health Laboratory, University of Nebraska Medical Center, Omaha, NE. 7. Division of Infection Control and Epidemiology, Nebraska Medicine, Omaha, NE. 8. Department of Anesthesiology, Division of Critical Care, University of Nebraska Medical Center, Omaha, NE. 9. Department of Emergency Medicine, University of Nebraska Medical Center, Omaha, NE. 10. Department of Emergency Medicine, University of Nebraska Medical Center, Omaha, NE; Nebraska Biocontainment Unit, Nebraska Medicine, Omaha, NE.
Abstract
INTRODUCTION: Due to the recent Ebola virus outbreak in West Africa, patients with epidemiologic risk for Ebola virus disease and symptoms consistent with Ebola virus disease are presenting to emergency departments (EDs) and clinics in the United States. These individuals, identified as a person under investigation for Ebola virus disease, are initially screened using a molecular assay for Ebola virus. If this initial test is negative and the person under investigation has been symptomatic for < 3 days, a repeat test is required after 3 days of symptoms to verify the negative result. In the time interval before the second test result is available, manifestations of the underlying disease process for the person under investigation, whether due to Ebola virus disease or some other etiology, may require further investigation to direct appropriate therapy. MATERIALS AND METHODS: ED administrators, physicians, and nurses proposed processes to provide care that is consistent with other ED patients. Biocontainment unit administrators, industrial hygienists, laboratory directors, physicians, and other medical personnel examined the ED processes and offered biocontainment unit personal protective equipment and process strategies designed to ensure safety for providers and patients. CONCLUSION: ED processes for the safe and timely evaluation and management of the person under investigation for Ebola virus disease are presented with the ultimate goals of protecting providers and ensuring a consistent level of care while confirmatory testing is pending.
INTRODUCTION: Due to the recent Ebola virus outbreak in West Africa, patients with epidemiologic risk for Ebola virus disease and symptoms consistent with Ebola virus disease are presenting to emergency departments (EDs) and clinics in the United States. These individuals, identified as a person under investigation for Ebola virus disease, are initially screened using a molecular assay for Ebola virus. If this initial test is negative and the person under investigation has been symptomatic for < 3 days, a repeat test is required after 3 days of symptoms to verify the negative result. In the time interval before the second test result is available, manifestations of the underlying disease process for the person under investigation, whether due to Ebola virus disease or some other etiology, may require further investigation to direct appropriate therapy. MATERIALS AND METHODS: ED administrators, physicians, and nurses proposed processes to provide care that is consistent with other ED patients. Biocontainment unit administrators, industrial hygienists, laboratory directors, physicians, and other medical personnel examined the ED processes and offered biocontainment unit personal protective equipment and process strategies designed to ensure safety for providers and patients. CONCLUSION: ED processes for the safe and timely evaluation and management of the person under investigation for Ebola virus disease are presented with the ultimate goals of protecting providers and ensuring a consistent level of care while confirmatory testing is pending.
Authors: Allison Gossen; Beth Mehring; Brian S Gunnell; Karen S Rheuban; David C Cattell-Gordon; Kyle B Enfield; Costi D Sifri Journal: Ann Am Thorac Soc Date: 2020-06
Authors: Aurora B Le; Sean A Buehler; Paul M Maniscalco; Pamela Lane; Lloyd E Rupp; Eric Ernest; Debra Von Seggern; Katherine West; Jocelyn J Herstein; Katelyn C Jelden; Elizabeth L Beam; Shawn G Gibbs; John J Lowe Journal: Am J Infect Control Date: 2018-03 Impact factor: 2.918
Authors: Aurora B Le; Selin Hoboy; Anne Germain; Hal Miller; Richard Thompson; Jocelyn J Herstein; Katelyn C Jelden; Elizabeth L Beam; Shawn G Gibbs; John J Lowe Journal: Am J Infect Control Date: 2017-09-25 Impact factor: 2.918
Authors: Elizabeth L Beam; Michelle M Schwedhelm; Kathleen C Boulter; Angela M Vasa; LuAnn Larson; Theodore J Cieslak; John J Lowe; Jocelyn J Herstein; Christopher J Kratochvil; Angela L Hewlett Journal: Nurs Clin North Am Date: 2019-03-26 Impact factor: 1.208
Authors: Dara Ann O'Keeffe; Dorothy Bradley; Linda Evans; Nirma Bustamante; Matthew Timmel; Roopa Akkineni; Deborah Mulloy; Eric Goralnick; Charles Pozner Journal: MedEdPORTAL Date: 2016-08-08